Trial · NCT07910916
Effects of Concurrent Training on Serum PCSK9 Levels in Adults With Overweight
NCT07910916, Not applicable, Recruiting, Kastamonu University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Concurrent Training on Serum PCSK9 Levels in Adults With Overweight. Trials, record NCT07910916. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910916
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Concurrent Training on Serum PCSK9 Levels in Adults With Overweight
- NCT number
- NCT07910916
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 42 participants, estimated
- Lead sponsor
- Kastamonu University
- Conditions
- Overweight, Lipid Metabolism, Cholesterol Metabolism
- Interventions
- Concurrent Aerobic and Resistance Training
- First posted
- 2026-11-02
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Serum PCSK9 Concentration | At baseline and 4 and 8 weeks after baseline | Serum PCSK9 concentration will be measured using an enzyme-linked immunosorbent assay (ELISA). Changes over time will be compared between the concurrent training and control groups. |
| Secondary | Change in Serum LDL Cholesterol Concentration | At baseline and 4 and 8 weeks after baseline | Serum low-density lipoprotein cholesterol (LDL-C) concentration will be assessed from fasting blood samples. Changes over time will be compared between the concurrent training and control groups. |
| Secondary | Change in Serum HDL Cholesterol Concentration | At baseline and 4 and 8 weeks after baseline | Serum high-density lipoprotein cholesterol (HDL-C) concentration will be assessed from fasting blood samples. Changes over time will be compared between the concurrent training and control groups. |
| Secondary | Change in Serum Total Cholesterol Concentration | At baseline and 4 and 8 weeks after baseline | Serum total cholesterol concentration will be measured from fasting blood samples using an enzymatic colorimetric method. Changes over time will be compared between groups. |
| Secondary | Change in Serum Triglyceride Concentration | At baseline and 4 and 8 weeks after baseline | Serum triglyceride concentration will be measured from fasting blood samples using an enzymatic colorimetric method. Changes over time will be compared between groups. |
| Secondary | Change in Fasting Serum Glucose Concentration | At baseline and 4 and 8 weeks after baseline | Fasting serum glucose concentration will be measured using an enzymatic colorimetric method. Changes over time will be compared between groups. |
| Secondary | Change in Body Weight | At baseline and 4 and 8 weeks after baseline | Body weight will be measured in kilograms (kg) using a digital scale (Tanita RD-545). |
| Secondary | Change in Body Mass Index | At baseline and 4 and 8 weeks after baseline | Body mass index (BMI) will be calculated as body weight in kilograms divided by height in meters squared (kg/m²). |
| Secondary | Change in Waist Circumference | At baseline and 4 and 8 weeks after baseline | Waist circumference will be measured in centimeters (cm) at the midpoint between the lowest rib and iliac crest. |
| Secondary | Change in Hip Circumference | At baseline and 4 and 8 weeks after baseline | Hip circumference will be measured in centimeters (cm) at the widest part of the hips. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910916
GET https://conductscience.org/api/trials/v1/NCT07910916/registered